Did the provider know about the patient’s 2–3‑week history of heightened anxiety/agitation, increased nocturnal cleaning, and prolonged derealization when recommending gabapentin?

Critical Context Gap in Gabapentin Recommendation

The provider's knowledge of the patient's 2-3 week history of heightened anxiety/agitation ("feeling wired"), increased nocturnal cleaning, and prolonged derealization is absolutely critical to evaluating the appropriateness of gabapentin in this case—and this recommendation would be highly questionable if these symptoms were unknown at the time of prescribing.

Why This Context Matters

Gabapentin's Psychiatric Side Effect Profile

The FDA label explicitly warns that gabapentin can cause serious behavioral and mood changes 1:

• New or worse anxiety
• Feeling agitated or restless
• Acting aggressive, being angry, or violent
• An extreme increase in activity and talking (mania)
• Other unusual changes in behavior or mood

These warnings are particularly emphasized for monitoring, with instructions to "pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings" 1.

Direct Evidence of Gabapentin-Induced Agitation

Multiple case reports document gabapentin causing the exact symptoms this patient is already experiencing:

• Two brain-injured patients developed "heightened anxiety and restlessness" within one week of 900 mg daily gabapentin, with symptoms resolving within 48 hours of discontinuation 2
• Two adults developed hypomanic features including "elevated mood, euphoria, increased energy, pressure of speech and decreased need for sleep" on gabapentin 3
• One patient developed "restlessness, disorientation, confusion, agitation, and anxiety" after gabapentin discontinuation, suggesting the drug had been masking or causing these symptoms 4

The Bipolar/Manic Concern

The constellation of symptoms—feeling "wired," increased nighttime activity (cleaning), and derealization—raises concern for a hypomanic or mixed state. This is critical because:

• Controlled studies in adults found gabapentin not helpful for bipolar disorder 5
• A 2022 systematic review concluded there is "minimal evidence" for gabapentin in bipolar disorder and it "should be used for these disorders only with strong justification" 6
• The FDA label specifically warns about "an extreme increase in activity and talking (mania)" as a potential adverse effect 1

Clinical Decision Algorithm

If the provider KNEW about these symptoms:

The recommendation becomes highly problematic because:

1. Gabapentin could worsen existing agitation/activation based on documented case reports 2, 3
2. The symptom pattern suggests possible hypomania/mixed state, for which gabapentin lacks evidence 5, 6
3. Prescribing a medication that can cause the exact symptoms the patient already has violates basic prescribing safety principles

If the provider DID NOT KNOW about these symptoms:

This represents a critical failure in clinical assessment because:

1. These symptoms are essential to diagnosis (anxiety disorder vs. bipolar spectrum vs. substance-induced)
2. They directly contraindicate or require extreme caution with gabapentin per FDA warnings 1
3. The treatment approach would differ fundamentally depending on the underlying diagnosis

What Should Have Been Done

Before prescribing gabapentin for anxiety in this clinical context, the provider must:

1. Rule out bipolar spectrum disorder through detailed history of mood episodes, family history, and response to prior treatments
2. Assess for substance use (gabapentin has abuse potential and withdrawal can mimic these symptoms 1, 4)
3. Evaluate the derealization (duration, triggers, relationship to mood symptoms)
4. Consider that "feeling wired" + increased activity + derealization could represent:
   • Hypomania/mixed episode
   • Severe anxiety with dissociation
   • Substance intoxication/withdrawal
   • Medication-induced activation (if on antidepressants)

Alternative Approaches Based on Symptom Pattern

If this represents anxiety with agitation:

• SSRIs/SNRIs remain first-line 7
• Buspirone for anxiety without sedation 8
• Short-term benzodiazepines with caution 8

If this represents bipolar spectrum:

• Mood stabilizers (lithium, valproate) or atypical antipsychotics (quetiapine, olanzapine) 5
• Avoid gabapentin given lack of efficacy evidence 5, 6

If this represents severe anxiety requiring gabapentinoid:

• Pregabalin has better evidence than gabapentin for generalized anxiety 6
• Start at lowest dose with explicit monitoring for worsening agitation 1

Bottom Line

Without knowing whether the provider was aware of these symptoms, you cannot fully evaluate the recommendation's appropriateness. If aware, the recommendation is concerning and potentially contraindicated. If unaware, this represents inadequate assessment before prescribing a medication with significant psychiatric side effects. Either scenario is problematic, but for different reasons—one reflects poor clinical judgment despite adequate information, the other reflects inadequate information gathering before prescribing.